American Medical Association. Pharmaceutical Benefits Management Companies , Report of the Board of Trustees . Chicago: AMA; 1997.
American Society of Health-System Pharmacists (ASHP). Best Practices for Health-System Pharmacy . Bethesda, MD: ASHP; 1998.
American Society of Hospital Pharmacists. ASHP guidelines for the scientific and therapeutic evaluation of drugs for hospital formularies. Am. J. Hosp. Pharm. 1981; 38:1043–1044.
American Society of Hospital Pharmacists. Therapeutic Interchange . Bethesda, MD: ASHP; 1982.
American Society of Hospital Pharmacists. ASHP statement on the formulary system. Am. J. Hosp. Pharm. 1983; 40:1384–1385.
American Society of Hospital Pharmacists. ASHP technical assistance bulletin on the evaluation of drugs for formularies. Am. J. Hosp. Pharm. 1988; 45:386–387.
American Society of Hospital Pharmacists. Am J. Hosp. Pharm. 1991.
American Society of Hospital Pharmacists. ASHP statement on the pharmacy and therapeutics committee. Am. J. Hosp. Pharm. 1992; 49:2008–2009.
American Society of Hospital Pharmacists. 1996
American Society of Hospital Pharmacists, APA, AHA, AMA. Statement of guiding principles on the operation of the hospital formulary system. Am. J. Hosp. Pharm. 1964; 21:40–41.
Anonymous. An interview with John Ogden. Am. Pharm. 1988; NS28:8:22–23.
Ascione FJ, Bagozzi RP, Mannebach MA, et al.. Analysis of the Internal and External Factors Related to Performance of Pharmacy and Therapeutic Committees . Ann Arbor: University of Michigan; 1998.
Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am. J. Med. 1982; 73:4–8.
Avorn J, Soumerai SB. Improving drug-therapy decisions through educational out-reach—A randomized controlled trial of academically based “detailing.” N. Engl. J. Med. 1983; 308(24):1457–1463.
Baciewicz AM, Cowan RI, Michaels PE, Kyllonen KS. Quality and productivity assessment of clinical pharmacy interventions . Hosp. Formul 1994; 29:773–779.
Bajpai SK, Pathak DS. Predicting formulary decisions in health maintenance organizations involving nonsteroidal anti-inflammatory drugs. J. Res. Pharmaceut. Econ. 1998; 9(1):57–70.
Bakke OM. How many drugs do we need? World Health Forum . 1986; 7:252–255.
Barents Group LLC. Analysis of Benefits Offered by Medicare HMOs, 1999: Complexities and Implications . Menlo Park, CA: The Henry J. Kaiser Family Foundation; 1999a.
Barents Group LLC. Factors Affecting the Growth of Prescription Drug Expenditures . Washington, DC: National Institute for Health Care Management Research and Educational Foundation; 1999b.
Barksdale Air Force Base. Dihydropyridine switch program deemed not cost effective. Formulary . 1998; 33:12.
Bartlett S, Marshall JA, Prochazka A, et al. A Study of the Short-Term Clinical and Economic Outcomes of Converting Hypertensive Patients from Long-Acting Nifedipine to Short-Acting Nifedipine . Denver: Department of Veterans Affairs Medical Center(unpublished) ; 1996.